Wall Street hospital investments in India trigger backlash over rising medical bills

Global private equity firms have poured some $10 billion into Indian hospital chains over the past five years, sparking a major political and economic battle over rising patient bills and healthcare costs.

The influx of foreign capital—led by Wall Street giants including KKR, Blackstone, TPG, and General Atlantic—has funded rapid consolidation and high-tech expansion across India's private healthcare sector. But it has also triggered a fierce backlash. In August, a parliamentary committee warned that an "unchecked influx of foreign capital" was allowing large corporate groups to buy up cost-effective, midsize hospitals. The panel recommended that the government reconsider foreign investment rules for healthcare, examine price caps, and set up a dedicated hospital regulator.

For private equity, India's healthcare sector presented a classic supply-and-demand opportunity. The country has just 1.3 hospital beds per 1,000 people, well below international standards, while a growing middle class is seeking treatment for complex conditions like cancer and heart disease.

These investments have yielded spectacular returns. Temasek Holdings generated a tenfold return on its investment in Manipal Health Enterprises after a partial stake sale in July, recording an internal rate of return of about 30 per cent, according to private markets data provider VCCircle. KKR is also expanding aggressively, agreeing in August to buy the Indian operations of Swedish chain Medicover for $1.4 billion, nearly doubling its southern Indian bed count to 10,000. Ratings agency Crisil expects private hospital revenues to grow by up to 15 per cent in fiscal 2027.

The fight over medical billing

But health insurers and consumer advocates argue that these returns are being squeezed out of patients. Medical inflation in India is running as high as 13 per cent annually, according to the parliamentary report, and private treatments cost five to ten times more than those in the public health system.

Insurers claim that private networks, particularly those backed by private equity, are inflating bills and pushing patients toward expensive, unnecessary procedures. "For all the benefits of private equity fund infusion, the tax we have to pay is higher cost," says S. Prakash, chief executive of the General Insurance Council’s Health Insurance Ecosystem. Insurers point to procedures like robot-assisted surgeries, which can cost significantly more than conventional methods without offering better clinical results.

Hospitals defend the costs, arguing that advanced technology improves patient outcomes and that slow insurance payouts squeeze their operating margins. But patients are caught in the middle, often forced to pay the difference out of pocket when insurers refuse to cover high-tech treatments.

Investors warn of regulatory chill

The battle is now threatening to deter future investment. Jean Eric Salata, chair of EQT Group—which owns stakes in Indira IVF and the Asian Institute of Gastroenterology—warned that regulatory price controls would undermine India's business climate. "It will be counter to the trend of deregulation," Salata said in September, adding that price caps would discourage further foreign investment.

Without a resolution, the friction is set to worsen. Animesh Das, chief executive of Acko General Insurance, warned that "the missing middle"—Indians who do not qualify for government aid but cannot afford soaring private bills—will bear the brunt of the standoff.